VIDEO: Neoadjuvant immunotherapy ‘shows a lot of promise’ in early-stage NSCLC

ByJae Y. Kim, MD

ByMarley V. Ghizzone

Healio spoke with Jae Y. Kim, MD, about a study presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.

The trial investigated neoadjuvant pembrolizumab in early-stage non-small cell lung cancer.

“It’s an exciting area of research for patients who are in early-stage disease,” Kim, chief of thoracic surgery and associate professor at City of Hope, said.

Reference:

Bar J, et al. Abstract OA11.01. Presented at: International Association for the Study of Lung Cancer World Conference on Lung Cancer (virtual meeting); Sept. 8-14, 2021.

Published by:

Sources/Disclosures

Collapse

Source: Healio Interview

Disclosures: Kim reports receiving a research grant to his institution from Eli Lily and serving as a consultant for AstraZeneca.

Take Homes in Lung Cancer

Read more

VIDEO: Neoadjuvant immunotherapy ‘shows a lot of promise’ in early-stage NSCLC

Reference:

Related Content